> [Original Message] > From: CDER MEDWATCH LISTSERV <[EMAIL PROTECTED]> > To: <[EMAIL PROTECTED]> > Date: 3/29/2007 3:01:52 PM > Subject: FDA - MedWatch - Permax (pergolide)- Product Market Withdrawal - New Studies Showed That Some Patients With Parkinson's Disease on Drug Had Serious Damage To Their Heart Valves > > MedWatch - The FDA Safety Information and Adverse Event Reporting Program > > FDA notified healthcare professionals and patients that companies that > manufacture and distribute pergolide have agreed to withdraw the drug > from the market. Pergolide is a dopamine agonist (DA) used with > levodopa and carbidopa to manage the signs and symptoms of Parkinson's > disease. Results of two new studies showed that some patients with > Parkinson's disease treated with pergolide had serious damage to their > heart valves when compared to patients who did not receive the drug. > These two studies confirm earlier studies that also described this > problem. Patients currently taking pergolide should contact their > healthcare professional about alternate treatments and not abruptly stop > taking their medication. Healthcare professions should assess their > patient's need for DA therapy. If continued treatment with a DA is > needed, another DA should be substituted for pergolide. > > Read the complete MedWatch 2007 Safety summary, including a link to the > FDA Public Health Advisory regarding this issue at: > http://www.fda.gov/medwatch/safety/2007/safety07.htm#Pergolide > > _________________________________________________________________ > > To ensure delivery of these timely alerts to your in-box and prevent rejection of the notice by a spam filter, please add our MedWatch address, [EMAIL PROTECTED], to your address book. > > Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch. > > To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm > > To unsubscribe from this listserve: > https://list.nih.gov/cgi-bin/wa?SUBED1=medwatch&A=1
